Key Takeaways
- • Health tech venture capital funding contracted significantly, declining approximately 30% from US$39.3 billion in 2021 to US$27.5 billion in 2022, reflecting market correction after elevated pandemic-era investment levels.
- • Provider operations captured 44% of health tech investment dollars, positioning the sector for its largest funding year on record if current investment velocity continues.
- • Digital therapeutics investments have sustained robust growth, averaging 40% annually over the past seven years, demonstrating sustained investor confidence in software-based clinical interventions.
- • Mega-deal activity in AI-driven health tech is accelerating, with $300 million-plus transactions representing an expanding share of venture capital deployment in the sector.
- • High-growth investment opportunities remain concentrated in telemedicine platforms, AI-powered diagnostics, remote monitoring technologies, wearable devices, and electronic health record systems.
Summary
The health tech investment landscape experienced notable contraction in 2022 following exceptional pandemic-era funding levels, according to Deloitte Insights analysis. Venture capital funding declined approximately 30% year-over-year, falling from US$39.3 billion in 2021 to US$27.5 billion in 2022. This pullback reflects broader venture market dynamics and investor recalibration following the elevated allocation rates of 2020-2021, though the sector remains substantially funded relative to historical baselines.
Despite near-term funding pressure, digital therapeutics continue to demonstrate resilience as an investment category. McKinsey & Company research indicates that U.S. investments in digital-therapeutics companies have grown at an average annual rate of 40% over the past seven years, underscoring sustained institutional confidence in this segment. This performance differential suggests investor differentiation between core health tech infrastructure and therapeutic software applications.
Provider operations have emerged as the dominant investment destination within health tech, capturing 44% of total investment dollars deployed across the sector. This concentration reflects the strategic imperative for healthcare systems to modernize operational workflows, enhance care coordination, and reduce administrative friction—areas where capital deployment can generate measurable ROI. According to the Future of Healthtech 2025 Report, the provider operations vertical is positioned to achieve its largest funding year on record if current investment pacing continues.
Mega-deal activity is reshaping the competitive landscape, with venture capital increasingly concentrated in large-scale AI and digital health transactions. Silicon Valley Bank research documents that more healthcare venture capital investment went to $300 million-plus AI deals in 2025 than in any other year measured, indicating investor preference for mature, well-capitalized platforms with proven commercialization pathways and substantial addressable markets.
Core investment themes remain focused on digital transformation infrastructure: telemedicine expansion, AI-driven diagnostic systems, remote patient monitoring technologies, wearable medical devices, and next-generation electronic health record platforms. These verticals address fundamental pain points across care delivery, clinical decision support, and patient engagement—areas where technology deployment can improve both clinical outcomes and operational economics.
Despite near-term funding pressure, digital therapeutics continue to demonstrate resilience as an investment category. McKinsey & Company research indicates that U.S. investments in digital-therapeutics companies have grown at an average annual rate of 40% over the past seven years, underscoring sustained institutional confidence in this segment. This performance differential suggests investor differentiation between core health tech infrastructure and therapeutic software applications.
Provider operations have emerged as the dominant investment destination within health tech, capturing 44% of total investment dollars deployed across the sector. This concentration reflects the strategic imperative for healthcare systems to modernize operational workflows, enhance care coordination, and reduce administrative friction—areas where capital deployment can generate measurable ROI. According to the Future of Healthtech 2025 Report, the provider operations vertical is positioned to achieve its largest funding year on record if current investment pacing continues.
Mega-deal activity is reshaping the competitive landscape, with venture capital increasingly concentrated in large-scale AI and digital health transactions. Silicon Valley Bank research documents that more healthcare venture capital investment went to $300 million-plus AI deals in 2025 than in any other year measured, indicating investor preference for mature, well-capitalized platforms with proven commercialization pathways and substantial addressable markets.
Core investment themes remain focused on digital transformation infrastructure: telemedicine expansion, AI-driven diagnostic systems, remote patient monitoring technologies, wearable medical devices, and next-generation electronic health record platforms. These verticals address fundamental pain points across care delivery, clinical decision support, and patient engagement—areas where technology deployment can improve both clinical outcomes and operational economics.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.